#161201

MCF10A-ERRB2m-12 cell line

Please Enter Your Email ID
Email ID

Cat. #161201

MCF10A-ERRB2m-12 cell line

Cat. #: 161201

Sub-type: Continuous

Organism: Human

Tissue: Mammarygland epithelium

Model: Mutant

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Medical-Industrial Translational Research Center

Institute: Fukushima Medical University

Primary Citation: Irie et al. Mol Cancer Ther. 2019 Apr, 18(4):733-742. PMID: 30787176

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: MCF10A-ERRB2m-12 cell line
  • Alternate name: 06M15014
  • Cancers detailed: Non-tumorigenic
  • Research fields: Cancer;Cell biology
  • Tool sub type: Continuous
  • Parental cell: MCF10A, a non-tumorigenic cell line from human mammarygland epithelium
  • Clone: ERBB2_type-13
  • Organism: Human
  • Tissue: Mammarygland epithelium
  • Morphology: Epithelial
  • Growth properties: Adherent
  • Model: Mutant
  • Model description: Type-13; Type mutation: R896C; CDS mutation: c.2686C>T; AA mutation: p.R896C; COSMIC Mutation ID: COSM14066
  • Description: Non-tumorigenic immortalized breast epithelial cell stably overexpressing mutant cancer-related gene, ERBB2 (erb-B2 Receptor Tyrosine Kinase 2). ERBB2 is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors.
  • Application: Functional analysis of mutated genes, Drug screening
  • Biosafety level: 1

Target Details

  • Target: Erb-b2 receptor tyrosine kinase 2 [ERBB2]
  • Target background: Gene ID: 2064; References: DNA (mRNA): NM_004448.3; Protein: NP_004439.2

Applications

  • Application: Functional analysis of mutated genes, Drug screening

Handling

  • Format: Frozen
  • Growth medium: DMEM/Ham's F-12 supplemented with 5% heat-inactivated horse serum, 10 Â?g/ml insulin (human, recombinant), 5 Â?M forskolin, 0.5 Â?g/ml hydrocortisone, 20 ng/ml EGF (human, recombinant), 100 U/ml penicillin, and 100 Â?g/ml streptomycin
  • Temperature: 37° C
  • Atmosphere: Humidified incubator with 5% CO2
  • Shipping conditions: Dry ice
  • Storage medium: CELLBANKER 2 (Zenogen pharma)
  • Storage conditions: Liquid Nitrogen
  • Initial handling information: Thaw the vial at 37 °C in a water bath?then seed cells into a T75 flask. Culture in a humidified Incubator at 37 ? with 5% CO2 in air. Culture medium should be changed every 2 to 3 days.
  • Cultured in antibiotics: 100 U/ml Penicillin, and 100 Â?g/ml Streptomycin
  • Mycoplasma free: Yes
  • Characterisation tests: Comprehensive gene expression analysis; Identification of cell proliferation and cellular form; Drug sensitivity tests

References

  • Irie et al. Mol Cancer Ther. 2019 Apr, 18(4):733-742. PMID: 30787176